Pricing for survival
BY Katie Dahler, National Life Sciences Leader, KPMG As demand for pharmaceutical cost containment intensifies, novel drug-pricing approaches are critical. First, an unprecedented number of blockbuster drugs came off patent over the last decade, and manufacturers were not able to pump out new drug innovations fast enough to replace them. The result was that sales and profit growth for most major pharmaceutical companies fell from double digits to low single digits. Although many...











